Physician profile
Rangappa Rajendra
NPI 1205843810
$5,999.41
in general payments reported to CMS, 2019-2025
41 companies · $1,096 in 2025
The $1,096 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $115 · 2021: $110 · 2022: $1,567 · 2023: $1,208 · 2024: $1,566 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Consulting Fee: $1,617 · Long Term Medical Supply Or Device Loan: $199 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.64 |
| Consulting Fee | $1,617.25 |
| Long Term Medical Supply Or Device Loan | $199.40 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,802.67 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Cti Biopharma Corp. | $1,437.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $638.90 | 2023-2025 | |
| Gilead Sciences, INC. | $185.73 | 2021-2025 | Trodelvy |
| Abbvie INC. | $181.24 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $144.11 | 2023-2024 | Tavalisse, Rezlidhia |
| Janssen Biotech, INC. | $137.18 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Intuitive Surgical, INC. | $116.25 | 2023 | |
| Merck Sharp & Dohme LLC | $106.22 | 2020-2025 | Keytruda, Lynparza |
| Caris Mpi, INC. | $91.43 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $90.36 | 2019-2025 | Polivy |
| Pfizer INC. | $87.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $83.70 | 2020-2025 | Blenrep, Ojjaara |
| Myriad Genetic Laboratories, INC. | $57.12 | 2021-2025 | Myrisk |
| Array Biopharma INC | $56.76 | 2021-2025 | Braftovi, Mektovi, Tukysa |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rangappa Rajendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.